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al., 1999). Nevertheless, a consensus I-Ag7 binding motif
has been difficult to establish from the sequence analy-
sis and binding studies of naturally processed and syn-
thetic peptides. One complication arises from the pro-
posed weak interaction of I-Ag7 with peptides (Reich et
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Christopher A. Nelson,* Osami Kanagawa,*
Emil R. Unanue,* and Daved H. Fremont*²³
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²Molecular Biophysics Program
Washington University School of Medicine al., 1994; Carrasco-Marin et al., 1999). Experiments have
shown that metabolically labeled I-Ag7 molecules are660 South Euclid Avenue, Box 8118
St. Louis, Missouri 63110 more susceptible to SDS denaturation (Carrasco-Marin
et al., 1996) (measured by SDS-PAGE with nonboiled
complexes) in comparison to several other MHC class
II alleles (Sadegh-Nasseri and Germain, 1991; Nelson etSummary
al., 1993).
A relatively unstable I-Ag7 may result in inefficient neg-We have determined the crystal structure of I-Ag7, an
ative selection and escape of autoreactive cells fromintegral component in murine type I diabetes develop-
the thymus (Carrasco-Marin et al., 1996), analogous toment. Several features distinguish I-Ag7 from other
a situation described with I-Au and encephalitogenicnon-autoimmune-associated MHC class II molecules,
peptides (Fairchild et al., 1993). In general, NOD miceincluding novel peptide and heterodimer pairing inter-
do possess a high frequency of autoreactive T cellsactions. The binding groove of I-Ag7 is unusual at both
(Kanagawa et al., 1998). Indeed, several NOD T cellsterminal ends, with a potentially solvent-exposed
specific to self antigens (i.e., GAD65) (Chao and McDev-channel at the base of the P1 pocket and a widened
itt, 1997; Reich et al. 1994) have been identified andentrance to the P9 pocket. Peptide binding studies
found under certain circumstances to induce diabeteswith variants of the hen egg lysozyme I-Ag7 epitope
(Tisch et al., 1993; Zekzer et al., 1998).HEL(11±25) support a comprehensive structure-based
In order to better understand its unique properties,I-Ag7 binding motif. Residues critical for T cell recogni-
we determined the 3.1 AÊ resolution crystal structure oftion were investigated with a panel of HEL(11±25)-
a soluble version of I-Ag7 in complex with the HEL(11±25)restricted clones, which uncovered P1 anchor±depen-
peptide. This epitope dominates I-Ag7-restricted T celldent structural variations. These results establish a
responses to HEL (Deng et al., 1993). Moreover, weframework for future experiments directed at under-
measured the binding of variant HEL(11±25) peptidesstanding the role of I-Ag7 in autoimmunity.
by exploiting the rapid dissociation of CLIP from I-Ag7.
In addition, we utilized I-Ag7-bearing antigen presenting
cells and variant peptides to map HEL residues criticalIntroduction
to recognition by a panel of T cell clones.
Although several genetic loci contribute to susceptibil-
ity, development of autoimmune, insulin-dependent dia- Results
betes (IDDM) in both humans and mice is strongly linked
to their MHC class II genotypes (reviewed by Castano Class II Structural Comparison
and Eisenbarth, 1990; Kikutani and Makino, 1992; Wong I-Ag7/peptide complexes with their transmembrane and
and Janeway, 1999). Genetic mapping and cloning of the cytoplasmic regions replaced with leucine zipper tails
NOD MHC locus identified the diabetes susceptibility and a HEL(11±25) peptide covalently attached to the b
haplotype, I-Ag7, which shares the same a chain as I-Ad chain were expressed using the recombinant baculovi-
but has a unique b chain (Choi et al., 1983; Acha-Orbea rus system. The structure of the thrombin-treated I-Ag7
and McDevitt, 1987). I-Ag7's substitution of the highly heterodimer was determined to 3.1 AÊ resolution with
conserved Prob56 and Aspb57 residues (PD) with two complexes in the asymmetric unit of a tetragonal
Hisb56 and Serb57 is closely associated with disease crystal form. I-Ag7 is very similar to the growing family
development (Todd et al., 1987). Introduction of PD into of human and murine MHC class II structures (Stern et
I-Ag7 protects transgenic NOD mice from diabetes (Lund al., 1994; Ghosh et al., 1995; Fremont et al., 1996, 1998;
et al., 1990; Quartey-Papafio et al., 1995; Singer et al., Dessen et al., 1997; Scott et al., 1998; Smith et al., 1998).
1998). The b chains of the human IDDM susceptibility The overall topology of I-Ag7 is consistent with other I-A
class II genes HLA-DQ2 and HLA-DQ8 also share a re- structures, although the b2 domain orientation is slightly
placement of Aspb57. altered (Figure 1A). Class II polymorphic residues cluster
Several studies examining foreign and self peptides around the I-Ag7 binding platform, especially at positions
have sought to define a general I-Ag7 binding motif in that contact peptide (Figure 1B). Common to I-Ad and
order to uncover potential diabetogenic peptides (Reich I-Ak, I-Ag7 contains a and b chain insertions relative to
et al., 1994; Amor et al., 1996; Harrison et al., 1997; Reizis HLA-DR and I-E (Glya9a and Glub84a). In addition, I-Ag7
et al., 1997; Carrasco-Marin et al., 1999; Hausmann et and I-Ak share a two-residue deletion at b65±b66 in the
b1 domain helical region. The core binding platform of
I-Ag7 has unique structural features primarily localized³ To whom correspondence should be addressed (e-mail: fremont@
immunology.wustl.edu). to the terminal ends of the peptide binding groove.
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Figure 1. I-Ag7 Structure Comparison
(A) Comparison of I-Ag7 (a chain in cyan and b chain in magenta) with I-Ad (white) and I-Ak (gray). The molecules are displayed as Ca ribbons
(Carson, 1987), with the peptide binding platform oriented toward the top. The binding platform of I-Ag7 is no more similar to I-Ad than I-Ak
and has an rmsD of 0.86 AÊ compared to I-Ad and 0.85 AÊ compared to I-Ak (based on main chain positions for residues Hisa5 through Asna84
and Hisb6 through Leub94, excluding I-Ad b65±b66). The most notable structural differences in the I-Ag7 binding platform occur at the ends
of the peptide binding groove, with alterations visible in the aH1 and bH1 helical regions. The bound peptide (for I-Ag7, shown in yellow)
displays the usual extended conformation.
(B) Peptide binding platform of I-Ag7. Although I-Ag7 and I-Ad share a common a chain, the I-Ag7 and I-Ak a chains differ at seventeen positions.
Fourteen of these differences are shown with side chains in cyan. Two remaining differences (Lysa138 and Trpa143) lie in the a2 domain and
are not shown. The b1 domain of I-Ag7 differs from both I-Ad and I-Ak at seven positions (Aspb2, Leub38, Hisb56, Serb57, Tyrb61, Glub84a,
and Valb87). I-Ag7 differs by five additional residues from I-Ak (Lysb12, Glyb13, Glub14, Thrb28, and Alab78), and by eight additional residues
from I-Ad (Hisb9, Pheb17, Pheb40, Lysb63, Tyrb67, Leub75, Thrb85, and Prob88). b chain residues are displayed in magenta and the HEL
peptide in yellow.
(C) Chain pairing in the P1 pocket. A displacement of the I-Ag7 aH1 helical region relative to its position in the other two structures is clearly
visible. The repositioning of the hydrophobic residues Leua45, Phea48, Leua51, and Ilea52 in I-Ag7 results in a large P1 pocket that is opened
up at its base where the HEL Arg14 salt bridges with Glub86 (hydrogen bonds represented as green balls). In I-Ak, a salt bridge forms at the
base of the P1 pocket between Arga52 and Glub86. In I-Ad, Ilea52 occupies part of the P1 pocket, while this same residue is pushed up and
out of the pocket in I-Ag7.
(D) The C-terminal end of the peptide binding groove. Several polymorphisms in I-Ag7 lead to a slight displacement of the bH1 helical segment
relative to its position in I-Ak and I-Ad. These differences include substitution of the highly conserved Prob56 and Aspb57 with Hisb56 and
Serb57. The salt bridge typically formed between Arga76 and Aspb57 is missing in I-Ag7, although it has been replaced by a similar hydrogen
bonding scheme that includes a buried solvent molecule associated with Serb57. Replacement of Prob56 by Hisb56 in I-Ag7, as well as two
novel peptide backbone interactions established by Tyrb61 and Tyrb67, also is associated with the altered conformation of the bH1 helical
segment.
I-Ag7 Chain Pairing P9 pocket area. I-Ag7b shares identity with I-Adb in the
central platform region (b10±b16), which allows for simi-Class II molecules have three main areas of heterodi-
meric contact in their platform domains: the central strand lar stabilizing interactions both above and below the
platform in both structures. In this region, there is aninterface, the region lateral to the P1 pocket, and the
Structure of an I-Ag7/HEL Peptide Complex
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Figure 2. I-A Binding Groove Comparison
I-Ag7 has a distinct peptide binding groove. Shown are comparisons of the molecular surfaces of I-Ag7, I-Ad, and I-Ak as viewed from the C-ter-
minal end of the binding groove. Surfaces were calculated with a 1.4 AÊ probe radius (Nichols et al., 1991). Polymorphic a chain residues
of I-Ag7 compared to I-Ak are highlighted in cyan. b chain residues that differ between I-Ag7 and either I-Ad or I-Ak are highlighted in magenta.
Pockets lining the binding groove are labeled P1±P9. The I-Ag7 P1 pocket is partially formed by the rearranged aH1 helix and contains an
unique opening at its base. The I-Ag7 P9 pocket, as a result of the PD substitution and bH1 rearrangements, has a lower outer rim (*) than
observed in other class II molecules. An I-Ag7 Ca trace is colored to highlight regions that are uniquely positioned in I-Ag7 relative to I-Ak and
I-Ad. Normalized differences comparing I-Ag7 to I-Ak and I-Ad relative to differences between I-Ak and I-Ad were calculated for all platform
residue main chain atoms [([I-Ag7 vs. I-Ak] 1 [I-Ag7 vs. I-Ad])/(2[I-Ak vs. I-Ad])] and are colored white to green on a color scale of 0±2.5. I-Ad
residues b65±b66 were excluded from the calculation. Significant normalized differences are localized to a43±a48, a51±a54, a84, and b88±b89.
Note that although additional significant differences exist between I-Ag7 and either I-Ak or I-Ad, individually these variations will not be highlighted
if I-Ak and I-Ad residues differ significantly as well (i.e., the bH1 helical regions).
interaction between Hisb9 and Glua66 (Figure 1D), resi- closely resembles I-Au and I-Ak, with identity at the poly-
morphic interface residues Thrb85 and Prob88. Struc-dues rarely encoded together by class II genes. How-
ever, in the terminal regions of the groove, I-Ag7 has tural comparison of I-Ag7 with I-Ad and I-Ak reveals a
significant reorganization of the I-Ag7 aH1 region (a45±substitutions that may not be well matched between the
two chains. The mismatching of these residues can lead a52), with several key pairing residues repositioned (Fig-
ure 1C). In the I-Ad/HA crystal structure, Ilea52 makesto significantly decreased heterodimer surface expres-
sion, as is the case of I-Ada/I-Akb hybrids (Sant et al., a hydrophobic contact with Prob85, forming the rim of
the P1 pocket (Scott et al., 1998). In the I-Ag7/HEL com-1991).
The P1 Channel plex, Ilea52 establishes hydrophobic contacts with
Thrb85 and Prob88 considerably higher in the groove,In comparison to other I-A alleles, the sequence of the
I-Ag7b region flanking the P1 pocket (residues b85±b90) which results in a wider pocket opening (Figure 2). HEL
Immunity
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Figure 3. HEL(11±25) Conformation and Interactions
(A) Electron density for the HEL(11±25) peptide. The simulated annealing omit map (CNS) for the region within 8 AÊ of the peptide is shown in
cyan at a contour of 2.5s. The map was constructed from the model phases by first omitting the peptide atoms from the calculation. The
HEL(11±25) peptide is displayed as a ball and stick figure: carbon atoms, yellow; nitrogen atoms, blue; sulfur atoms, green; and oxygen atoms,
red. This view is from the side, with the peptide anchor residues pointing downward.
(B) The I-Ag7 peptide backbone interaction strategy. Hydrogen bonds between the I-Ag7 molecule and backbone atoms in the HEL peptide are
represented as dashed lines. The diagram is orientated so that the peptide-flanking class II a chain helix is at the top with the peptide side
chains labeled as P22 through P10 (similar to Figure 1B). Two of the hydrogen bonding interactions are unique to I-Ag7 and have been
highlighted by filled boxes. First, the side chain of Tyrb61 reaches under the peptide main chain to hydrogen bond with the carbonyl oxygen
of P7. Second, the side chain of Tyrb67 reaches over the peptide main chain to hydrogen bond with the carbonyl oxygen of P8. In addition
to the main chain interactions, several I-Ag7 residues make contact with the side chains of the bound peptide and are listed at the bottom.
Arg14 is deeply buried at this site, interacting with the in I-Ad and I-Ak, potentially in a P1 anchor±dependent
manner (described below). Surprisingly, these alter-I-A invariant residues, Glub86 and Thrb89. Interestingly,
Arga52 in the I-Ak structure recapitulates these interac- ations generate a potentially solvent-exposed channel
at the base of the P1 pocket (Figure 2).tions, filling the base of the P1 pocket. The dominant
peptide anchor for I-Ak is an Asp at the P1 position, and The PD Substitution
The presence of Hisb56 and Serb57 makes I-Ag7b uniquethis residue braces the flanking regions of the a and b
chains into a network of hydrogen bonds (Fremont et from other I-A alleles. In all other known MHC class II
structures, Arga76 forms a salt bridge with Aspb57 andal., 1998). Evident from our I-Ag7/HEL structure are dis-
placements of Leua45, Phea48, and Leua51, situated the exposed carbonyl oxygen of Leub53, linking to-
gether the aH2 and bH1 helices. At the C-terminal endat the N-terminal end of the groove. In I-Ag7, these resi-
dues are repositioned by 2±3 AÊ relative to their location of the I-Ag7 binding groove, a number of factors including
Structure of an I-Ag7/HEL Peptide Complex
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Figure 4. I-Ag7 Pockets and Anchors
(A) Molecular surface of I-Ag7 looking down
into the peptide binding groove. Estimated
electrostatic potentials were calculated in
GRASP (Nichols et al., 1991); positive poten-
tial (20 mv) colored blue, neutral potential (0
mv) colored gray, and negative potential (220
mv) colored red. The binding pockets are la-
beled in yellow. The P1, P4, and P6 pockets
appear acidic in contrast to the more basic
P7 and P9 pockets.
(B) The solvent-accessible surface (Connolly,
1993) of the I-Ag7 peptide binding groove
(blue) viewed from the side as a cross section.
The HEL peptide is represented as a CPK
model: carbon atoms, yellow; nitrogen atoms,
blue; sulfur atoms, green; and oxygen atoms,
red. In addition to the usual peptide anchor
side chains (P1, P4, P6, P7, and P9), the P10
side chain also makes extensive contact with
the I-Ag7 molecule. The HEL peptide buries
81% (334 AÊ 2) of its main chain and 72%
(612 AÊ 2) of it side chain surface area.
(C) Proposed alignment of I-Ag7 binding pep-
tides. The upper panel lists eight different
I-Ag7 binding peptides: G6PI (glucose-6-phos-
phate isomerase, 282±294) (P. M. Allen, per-
sonal communication); GAD65a (glutamic
acid decarboxylase, 207±220) and GAD65b
(glutamic acid decarboxylase, 222±235) (Chao
and McDevitt, 1997); MSA (mouse serum al-
bumin, 563±573); Tnf (transferrin, 57±68); Apo
(apolipoprotein B, 100±113); Actin (actin, 73±
85); and Insulin (Insulinb, 10±23) (Rammensee
et al., 1999). The peptides were aligned based
on a structural analysis of the shape and
chemical nature of the binding groove.
Shown in the lower panel is a set of single
amino acid substitutions made at HEL(11±25)
anchor positions. Listed beside each peptide
sequence is an IC50 value, the concentration
of peptide required to inhibit 50% of the bind-
ing of a reference peptide to I-Ag7. NB, no
binding; ND, not determined.
the PD substitution modify the conformation and posi- peptide backbone as in other class II structures (Figure
3B) (Nelson and Fremont, 1999). There are several con-tion of the bH1 helix (Figure 1D). The I-Ag7 Hisb56 substi-
tution for Pro appears to allow an altered conformation served hydrogen bonds to the C-terminal half of the
peptide backbone, but also some surprises. The nearlyof the N-terminal region of the bH1 helix. A shift in the
C-terminal region of the helix repositions several resi- MHC invariant Trpb61 residue is substituted with Tyr in
I-Ag7b. Instead of making a hydrogen bond to the P8dues, including Tyrb61 and Tyrb67, which form peptide
backbone interactions. In I-Ag7, Arga76 takes part in carbonyl, the I-Ag7 Tyrb61 forms a hydrogen bond with
the P7 carbonyl oxygen from the underside of the pep-an extended hydrogen bonding network, establishing
interactions with Leub53 and Serb57. This later interac- tide (Figure 1D). Interestingly, the I-Ag7,f,s,u alleles that
have a Tyrb61 also share a Leub38, which in I-Ag7 sitstion is in part mediated via a buried water molecule that
sits closely associated with Serb57, coincident with the below the Tyrb61 phenol ring and supports its peptide
backbone interaction. The P8 carbonyl oxygen is hydro-Aspb57 carboxylate consensus position of other class
II molecules. As a result of these alterations, I-Ag7's P9 gen bonded to Tyrb67, which reaches above the pep-
tide, an interaction not observed with I-Ak, which sharespocket is open at the C-terminal end compared to other
MHC class II structures, which have a well-defined rim a Tyrb67.
The peptide binding groove contains four prominentat the end of the groove (Figure 2).
pockets consistent with the arrangement in previous
class II structures: P1, P4, P6, P9 (Figure 4A). I-Ag7 alsoI-Ag7 Interactions with HEL(11±25): Structural
and Binding Features forms a shallow P7 cleft, similar to one observed in I-Ak.
As a result of its binding to I-Ag7, the HEL(11±25) pep-The HEL peptide adopts the expected type II polyproline
helical conformation in the binding cleft, with the peptide tide buries 951 AÊ 2 of surface area (75% of the entire
solvent-accessible surface), more than observed to datedipping in the middle and rising toward the ends (Figure
3A). At the N-terminal half of the peptide, the I-Ag7 mole- in other murine class II complexes. The side chains of
HEL residues Arg14, Leu17, and Asn19 are completelycule makes similar conserved hydrogen bonds with the
Immunity
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Figure 5. Binding of HEL(11±25) to Soluble I-Ag7
(A) Schematic outline of the cDNA construct used to produce soluble I-Ag7 molecules. Chain pairing was encouraged by the addition of leucine
zipper acid and base tails at the C termini (Chang et al., 1994). A peptide (from HEL or CLIP) was encoded at the N terminus of the b chain
(Kozono et al., 1994). The soluble I-Ag7 protein was purified from baculovirus-infected insect cell supernatants and treated with thrombin to
release the peptide and leucine zipper tails.
(B) Representative curve for the binding of radiolabeled HEL(11±25) peptide to purified thrombin-cleaved I-Ag7. The inset panel contains a
Scatchard analysis of this binding, which yielded an apparent KD of 6.0 mM. The binding of HEL(48±61) peptide to soluble thrombin-cleaved
I-Ak performed under similar conditions yielded an apparent KD of 0.1 mM.
ensconced in the P1, P4, and P6 pockets, while Tyr20 P1 Pocket
is dominantly buried in the P7 ridge (Figure 4B). P9 is The HEL(11±25) Arg14 is deeply buried in the I-Ag7 P1
the only classical pocket not filled, over which Gly22 pocket, with its aliphatic portion making hydrophobic
passes leaving a large cavity of approximately 100 AÊ 3. contacts with Leua31, Phea32, and Thrb85. The Arg14
This cavity appears to contain a water molecule for both guanidinium forms extensive interactions with the I-A
complexes in the asymmetric unit. The electron density invariant residues Glub86 and Thrb89. In binding assays
for the P10 and P11 positions is not as well resolved as at pH 7.5, a conservative substitution of HEL(11±25)
the core peptide in the final model. It does appear that Arg14 with Lys binds equally well, as does a hydropho-
the Tyr23 P10 delves down along a ledge outside the bic Phe substitution (Figure 4C). An Ala P1 anchor sub-
binding groove burying a significant portion of the phe- stitution has no detectable effect on the binding or per-
nyl ring; however, it is not completely protected from sistence of the peptide with I-Ag7, suggesting that there
solvent. is no single obligate residue for this position. In contrast,
Described below are structural interactions of charge reversal of HEL Arg14 to Asp decreases binding.
HEL(11±25) residues with individual I-Ag7 binding groove Alignment of several peptide sequences indicates a gen-
pockets. Included are binding analyses of HEL(11±25) eral preference for hydrophobic and basic residues and
and variant peptides using peptide exchange of I-Ag7/ an absence of acidic residues as P1 anchors.
CLIP complexes. (Purified I-Ag7/CLIP molecules were P4 Pocket
cleaved with thrombin to release the covalently attached HEL Leu17 anchors into the medium-sized, hydrophobic
CLIP peptide and zipper tails to prepare the class II P4 pocket, which resembles the pocket found in I-Ad.
molecule for loading with exogenous peptides [Figure
The Leu17 side chain makes significant contact with
5A].) Together with a proposed sequence alignment of
Glyb13 and Leub26 from the floor of the groove andseveral other peptides (Figure 4C), these data provide
Alab78 from the spanning helix. These three polymor-an interpretation of the I-Ag7 allele±specific binding motif.
phic residues are shared between I-Ag7b and I-Adb. Sub-Scatchard analysis determined that the HEL(11±25)
stitution of Leu17 with Ala slightly reduces the relativepeptide binds I-Ag7 with an apparent affinity (KD) of 6.0
binding affinity of HEL(11±25). Replacement of the P4mM, approximately 50-fold less than the binding of the
pocket residue with Asn has a more significant effect,high affinity HEL peptide (48±61) to I-Ak (Figure 5B). The
decreasing the IC50 of HEL(11±25) by 5- to 6-fold. Anbound HEL(11±25) dissociates from I-Ag7 slowly over
Asp substitution of the P4 anchor does not bind. In othertime (.75% bound after 48 hr). However, despite the
I-Ag7 binding peptides, the P4 position is dominated bypersistence of these complexes, they are SDS-PAGE
Leu, Ile, and Val. The sequence preferences at the P4unstable. In comparison, I-Ak/CLIP exchanged with the
anchor position of I-Ad are similar, with a predominanceHEL(48±61) peptide forms complexes that are both SDS-
of small- or medium-sized hydrophobic residues (ScottPAGE resistant (78%) and long lived, with 95% still intact
after 48 hr. et al., 1998).
Structure of an I-Ag7/HEL Peptide Complex
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Figure 6. Presentation of HEL(11±25) Variants on I-Ag7
(A) Binding comparison at pH 7.5 and stimulatory capacity of various truncated HEL peptides. Truncation of the HEL(11±25) peptide to shorter
than the P-1 residue at the N terminus decreases I-Ag7 binding. At the C terminus, truncations past the P9 residue also cause a large drop in
binding. The relative ability of these truncated peptides to stimulate an I-Ag7-restricted T cell clone, D1, was measured. The results for each
peptide are listed on the left as an SC50 value, concentration required for half-maximal stimulation.
(B) Five T cell clones were tested for their recognition of Ala-substituted peptides. Raised in NOD mice, three of these T-cell clones, G1, G2,
and G3 are I-Ag7 restricted, while D1 and D2 react to the HEL(11±25) epitope presented on either I-Ag7 or I-Ad. The relative response of each
clone to 10 mM peptide is shown in the table (111 for maximal stimulation, 11 for moderate, 1 for slight, and 2 for undetectable). The
IC50 binding concentration of each peptide at pH 7.5 is given below the corresponding Ala substitution. The first column represents the
response to the wild-type HEL(11±25) peptide. Although these clones differed in their response profiles, the primary T cell contacts appear
to be the P2 His15, the P5 Asp18, and the P8 Arg21. Recognition of a P1 anchor Lys substitution is also shown.
P6 Pocket this is obligatory, as a wide array of residues appear
HEL Asn19 adjoins the shallow P6 pocket, where it to be accommodated. This may be due to the general
makes an extensive hydrophobic contact with Pheb11 plasticity of this site, the structure of which varies con-
and hydrogen bonds with Glua66. The P6 region of I-Ag7 siderably among different MHC proteins as well as be-
is smaller than the equivalent sites in either I-Ad or I-Ak, tween different peptide complexes of the same allele.
due in part to the combined presence of the interacting Due to the interplay of the P5 and P7 side chains, one
Glua66 and Hisb9. The binding of an Ala19-substituted might expect a coupling of specific residue pairs.
HEL peptide is slightly improved relative to Asn, while P9 Pocket
replacement with Leu or Glu considerably decreases HEL Gly22 is located above the I-Ag7 P9 pocket, leaving
binding. An Asn19 substitution to Tyr has no detectable a significantly sized cavity under the peptide main chain
binding. Small hydrophobic and polar residues appear (Figure 4B). The backbone of Gly22 is arrayed by its
to occupy this position in other peptide sequences (Ala, interactions with Asna68 and Hisa69, as observed in
Val, Thr, and Asn). other I-A complexes. The Gly22 Ca position makes hy-
P7 Pocket
drophobic contact with Tyrb61. For binding assays, we
The P7 pocket is a ledge along the b chain helical re-
individually substituted Asp and Glu for Gly22, since itgion containing the b65±b66 deletion, common to the
has been shown that a P9 acidic residue affords someI-Ag7,k,u,f,s alleles. However, the position and shape of the
peptides an advantage in binding I-Ag7 (Hausmann et al.I-Ag7 P7 pocket is different from that observed in I-Ak,
1999). The binding of these two P9-substituted peptidespartially due to the reorganization of the b chain dis-
occurs equally well at both acid and neutral pH's. Wecussed earlier. HEL Tyr20 is situated in the P7 ridge
find no apparent difference in the IC50, SDS-PAGE sta-where it stacks between the otherwise solvent-exposed
bility, or dissociation rate of the acid-substituted HELHEL Asp18 (P5) and the phenyl rings of Tyrb61 and
peptides compared to wild type. Ala substitution at P9Tyrb67. The Tyr20 hydroxyl group extends toward the
does not affect peptide binding, while Lys substitutionN terminus of the peptide and hydrogen bonds with
results in weaker binding and a more rapid off rate. TheGlub74. Substitution of Ala for Tyr20 has a major effect
alignment of other peptides indicates a strong Asp andon binding (Figure 4C). Alignment of a number of differ-
Glu preference at the P9 position, with Gly also ob-ent peptides suggests a potential enrichment for hy-
drophobic residues at P7; however, it is unlikely that served. An acidic residue at P9 would be well positioned
Immunity
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Table 1. Data Collection and Refinement Statistics for I-Ag7/HEL(11±25)
Space group P41212; 2 complexes/ASU
Unit cell dimensions (AÊ ) a 5 b 5 109.54, c 5 176.36
Data Processing
Resolution 20.0±3.1 (3.31±3.1)
Observations 102,791 (15,897)
Unique reflections 18,859 (3524)
Completeness (%) 93.7 (98.8)
I/s 6.0 (2.3)
Rmerge[a] (%) 12.9 (34.5)
Refinement F . 3s F . 0
Resolution 20.0±3.1 (3.29±3.1) 20.0±3.1 (3.29±3.1)
Reflections in working set 15,326 (2143) 17,909 (3048)
Reflections in test set 781 (112) 920 (167)
Completeness (%) 80.2 (69.0) 93.8 (98.4)
Rcryst (%) 22.1 (28.5) 24.0 (31.8)
Rfree (%) 29.9 (36.3) 31.3 (40.0)
RmsD for ideality bond lengths (AÊ ), angles (8) 0.01, 1.5
Number of nonhydrogen protein atoms 2 3 3156
Number of carbohydrate nonhydrogen atoms 2 3 42
Number of solvent atoms 72
Wilson B value 39.1
Average overall B value (AÊ 2) 36.4
Average peptide B value (AÊ 2) 48.5
Average solvent B value (AÊ 2) 14.8
Estimated coordinated error (AÊ ) 0.4±0.5
to take advantage of the cavity we observe in the P9 and MHC complex (Reinherz et al., 1999), the exposed
residues P2 (His14), P5 (Asp18), and P8 (Arg21) are allpocket, perhaps interacting with Serb57 and Arga76.
important for T cell recognition. Although Ala substitu-
tion of the P3 Gly does not affect peptide binding, itT Cell Recognition of HEL(11±25)
does influence T cell recognition, similar to the situationMinimal Epitope Mapping
described by Shibata et al. (1992).The core peptide required for T cell recognition was
T cell responses are also dependent on the residuesdetermined by the responsiveness of one representative
buried within the binding groove pockets. Ala substitu-T cell clone (D1) to truncated HEL(11±25) peptides pre-
tion of Arg14 (at P1) reduces or eliminates T cell activa-sented by I-Ag7-bearing NOD APC. Shortening of the
tion, while the conservative Lys substitution is recog-HEL(11±25) peptide beyond the P1 Arg14 severely de-
nized equally to the wild-type Arg. In addition, the P4creases T cell recognition of the epitope, as well as its
and P6 pocket sites are critical for several I-Ag7-specificbinding to I-Ag7 (Figure 6A). C-terminal truncations up
clones. The P7 (Tyr20) is involved in the recognitionto the P9 pocket are also recognized, while removal of
by three clones, two I-Ag7 specific and one I-Ad cross-residues beyond the P9 Gly22 abrogates both T cell
reactive. The ability of peptide anchor residues to influ-responses and peptide binding. The core HEL(14±22)
ence T cell responses has also been reported by a num-peptide stimulates poor responses and binds weakly,
ber of groups, including Boehncke et al. (1993).perhaps due to the loss of the interaction between the
P21 main chain (Lys21) and Hisb81 (Figure 3B).
T Cell Recognition of Peptide Residues Discussion
Peptide residues involved in T cell recognition were
identified by the ability of five different HEL(11±25)-spe- I-Ag7 is distinguished from most other class II molecules
by its rapid cell surface turnover, predominant popula-cific T cell clones to respond to Ala-substituted peptides
(Figure 6B). Two of these five clones were cross-reactive tion of SDS denaturation-susceptible molecules, overall
weak peptide binding, and by its Prob56 and Aspb57with HEL(11±25) presented in the context of I-Ad (clones
D1 and D2). Our panel of T cells requires similar profiles (PD) substitution. Comparison of I-Ag7/HEL with I-Ad and
I-Ak reveals significant alterations in the terminal regionsof critical residues with only a few differences observed
between them. Furthermore, the relative affinity of each of the binding groove. The P1 and P9 pockets are both
opened up, with a presumably greater access for sol-Ala-substituted peptide for I-Ag7 was measured to un-
cover substitutions that alter peptide binding (Fig- vent. These alterations may be responsible for the rela-
tive instability of I-Ag7/peptide complexes, thus theirure 6B).
Ala substitutions of either the amino (P23 and P22) rapid cell surface turnover. Nevertheless, the I-Ag7 struc-
ture reveals additional stabilizing interactions in the cen-or carboxyl ends (P10, P11, P12) outside the core pep-
tide have no effect on T cell recognition or peptide bind- tral groove that have not been observed in other class
II molecules. The novel I-Ag7 heterodimer pairing interac-ing. Two T cells (D2 and D3) are sensitive to the P21
position. As expected from the structure of the D10 TCR tions that create its modified groove may be the result of
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evolutionary pressures that are continuously fine-tuning generated by its remolded binding groove, we combined
the nature of the molecule in order to alter the specificity our structural and binding analyses with a sequence
of peptide binding. There is also a likely selective pres- alignment of several natural epitopes. This motif pre-
sure to keep class II molecules unstable in the absence sents several generalized rules for favored and disfa-
of peptide ligands, in order to encourage loading in the vored residues at individual I-Ag7 pockets, as follows.
appropriate vesicles with the aid of the invariant chain For P1, the P1 pocket appears to prefer hydrophobic and
and DM, while discouraging indiscriminate loading at positively charged residues, although this preference is
the cell surface. fairly flexible and no single residue predominates. The
An example of I-Ag7's remodeled structure compared acidic environment at the base of the P1 pocket appar-
to I-Ad occurs near the edge of the P1 site where Ilea52 ently disfavors acidic residue binding. For P4, the P4
is pushed up and out of the pocket, presumably in part pocket prefers hydrophobic residues, with a dominance
by the P1 Arg14 anchor itself. The effect of repositioning of Leu, Ile, and Val. Charged or hydrophilic residues are
this residue resonates across the main chain of the aH1 highly disfavored. For P6, the P6 pocket overwhelmingly
helix, displacing a number of pocket-lining residues prefers small hydrophobic and hydrophilic anchors,
away from the b chain. Thereby, several heterodimeric while larger side chain residues are disfavored. For P7,
contacts are broken and an opening forms at the base the P7 pocket has a general preference for hydrophobic
of the P1 pocket, factors that may enhance I-Ag7 instabil- residues. For P9, the P9 pocket appears to prefer Asp
ity. It is conceivable that bulky P1 anchor side chains, and Glu residues, although Gly and Ala appear tolerated.
like Arg14, may be responsible for splaying apart the a The slightly basic P9 environment favors the loading
and b chains, while complexes with small P1 anchors of acidic P9 anchors, while basic residues are clearly
may have a tighter knit pocket. This presumptive flexibil- inhibitory. Taken together, our structural analysis (Table
ity of the N-terminal binding groove region may allow 1), binding studies, and T cell recognition data have
I-Ag7 to adapt to diverse P1 anchors by forming distinct provided insight into some of the characteristics that
conformations. Our panel of T cells appears able to distinguish I-Ag7 from other non-diabetes-related class
distinguish aH1 rearrangements possibly imposed by II molecules.
the Arg14 P1 anchor, as all five clones we tested differ-
entially recognize the P1 Ala14 variant. However, con- Experimental Procedures
servative substitution of Arg14 with Lys allows for identi-
Expression Vector Constructioncal T cell recognition of the complexes, arguing that a
The pBacpHp10 shuttle vector (courtesy of J. Kappler) containingP1 Lys anchor induces a similar I-Ag7 conformation in
I-Ad leaders was used as a template for our constructs. The ectodo-the N-terminal groove region as Arg14. Following the
mains of either I-Ag7 or I-Ak were placed into the vector: a chainreview of this paper, the structure of I-Ag7 bound to a
sequences terminating after residues a178-WEPE-a181 and b chain
glutamic acid decarboxylase 65 peptide was reported sequences ending in b188-WRAQ-b191. Modified Fos/Jun leucine
by Corper et al. (2000). The P1 pocket of their structure zippers (Chang et al., 1994) were attached to the C terminus of
each chain via a polylinker containing thrombin cleavable sitesharboring an Ile peptide anchor resembles that of I-Ad,
(SSADLVPRGST). The a chain possessed the basic tail terminatedsupporting our interpretation of the malleability of the
with a 6-His tag. The acidic zipper tail was attached to the b chain.P1 pocket to specific peptide anchors. The structure of
The b chain construct also encoded a covalently linked peptide,the P9 pocket in their complex, which accommodates
either HEL(11-AMKRHGLDNYRGYSL-25) or CLIP(79-KLPKSAKPV
a Glu residue from the GAD peptide, appears indistin- SQMRMATPLLMRP-100). These peptides were attached near the
guishable from the conformation that our I-Ag7 P9 pocket N terminus of the mature b chain sequence via a poly-Gly/Ser linker
adopts with a Gly anchor residue. (Kozono et al., 1994), also possessing a thrombin cleavage site
(GGSLVPRGSGGGG).Specific contacts between the a and b chains are also
located at the P9 site. There has been speculation that
Protein Expression and Purificationthe PD substitution at the P9 pocket was partially re-
Baculoviruses were generated by CellFectin cotransfection (GIBCO-sponsible for I-Ag7's involvement in diabetes. Without
BRL) of SF9 insect cells with linearized baculovirus DNA (Phar-the salt bridge, I-Ag7 does have a more open-ended
mingen) and the pBac shuttle vector containing both a and b chains
binding groove and a remolded P9 pocket. Nonetheless, of either I-Ag7 or I-Ak. High five insect cells were grown to a density
Arga76 does make a number of favorable interactions of 4 3 105/ml with serum-free medium (Invitrogen) in spinner flasks.
with the I-Ag7 b chain, tying the heterodimer together. The cells were then infected with the baculovirus-containing super-
natants and incubated at 188C for 10 days postinfection. Superna-The substitution of a several residues in the bH1 helical
tants were harvested, concentrated, and exchanged into 10 mMsegment, including Hisb56, are associated with an al-
sodium phosphate (pH 5.6), 300 mM sodium chloride with a YM10tered conformation and position of this peptide flanking
Amicon spiral filtration cartridge in order to reduce their volume andhelix, a region previously described as a ªflexible seg-
remove excess free His. The supernatants were adjusted to pH
mentº in both class I and II (Fremont et al., 1992; Murthy 8.0 with 10 N sodium hydroxide and passed over Ni-NTA columns
and Stern, 1997) that potentially allows the binding of (Qiagen). After washing the column with 50 mM sodium phosphate
diverse peptide sequences. buffer (pH 8.0), 15 mM imidazole, 300 mM sodium chloride, the class
II proteins were eluted with the same buffer containing 250 mMOur results further support a number of proposed I-Ag7
imidazole, concentrated with a YM10 Amicon concentrator, andmotifs, especially those reporting that acidic residues
exchanged into 20 mM HEPES (pH 7.4), 150 mM sodium chloride,near the C-terminal end of I-Ag7 binding peptides are
0.02% sodium azide. Final protein yields were approximately 1 mgfavored (Reich et al., 1994; Hausmann et al., 1999; Ram-
of protein per liter of cell supernatant.
mensee et al., 1999). We have also observed a significant
role of Tyr20 in HEL(11±25) in I-Ag7 binding, as did Har- Crystallization and Data Collection
rison et al. (1997). In order to delineate a more compre- Crystallization of I-Ag7/HEL required removal of the zipper tails by
thrombin cleavage, which also cleaves the peptide linker. Purifiedhensive I-Ag7 binding motif that outlines the specificity
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I-Ag7/HEL molecules at 1 mg/ml were treated overnight with 1 U Peptide Binding
Peptide binding was examined under two conditions. First, 2±5 mgthrombin/mg protein (Novagen) at room temperature. The protein
was exchanged into 20 mM HEPES, 0.02% sodium azide (pH 7.4) I-Ag7/CLIP was treated with 0.1 U thrombin to cleave both the zipper
tails and peptide linker (Novagen) and simultaneously incubatedand concentrated to 10 mg/ml. Diffraction quality crystals of I-Ag7
formed at 208C in 10% PEG 5000 MME (Fluka), 100 mM sodium with 0.125 pmol of 125I-radiolabeled HEL(11±25) (labeled by the chlo-
ramine T method as described by Nelson et al. [1993]) and increasingacetate (pH 4.4), 10% ethylene glycol in vapor diffusion hanging
drops. These crystals grow as imperfect elongated rods with the doses of unlabeled peptides in 20 mM HEPES, 150 mM sodium
chloride (pH 7.4). Binding reactions were incubated overnight atbest crystal measuring approximately 0.1 3 0.1 3 0.4 mm. Crystals
were prepared for liquid nitrogen flash cooling by the addition of 258C in 30 ml volumes. Complexes were purified from free peptide by
gel filtration Bio-spin columns (Bio-Rad). The percentage of boundethylene glycol to the crystallization drop to a final concentration
of 20%. peptide was evaluated by gamma counting. Less than 0.5% of pep-
tides nonspecifically passed through the Bio-spin columns. In aCrystallographic data for the I-Ag7/HEL complex were collected
to 3.1 AÊ resolution from a single cryopreserved crystal with a Rigaku second approach, I-Ag7/CLIP protein was treated with 0.1 U thrombin
for 1 hr at 378C, and then stopped by the addition of PMSF to a 1rotating anode generator, operating at 50 kV and 100 mA, fitted with
Yale mirrors and an Raxis IV image plate detector (Table 1). Attempts mM final concentration. Aliquots were maintained at pH 7.5 or ad-
justed to pH 5.5 with 1 M MES, and binding reactions were per-to obtain higher resolution data, either at home or synchrotron
beamlines, have proved unsuccessful. Data from the best crystal formed as above. Binding affinities were estimated by Scatchard
analysis of HEL(11±25) peptide binding to I-Ag7 and HEL(48±61) bind-were indexed and processed (Otwinowski, 1993) in the primitive
tetragonal space group P422 with unit cell dimensions of a 5 b 5 ing to I-Ak. Individual binding results varied less than 20% from the
averaged value.109.54 AÊ and c 5 176.36 AÊ . These data were batch scaled using
SCALA (CCP4, 1994) with profile fitted full intensities and integrated
partials. Due to severe ice ring formations present during data col- Peptide Dissociation
lection, reflections between 3.72 AÊ and 3.67 AÊ resolution were hand MHC-labeled peptide complexes were isolated after a 24 hr binding
edited to remove poorly fit observations. The overall Rmerge of the reaction and incubated with a 1000-fold excess of unlabeled pep-
data is 12.9% for all 20±3.1 AÊ reflections, which are 5.5-fold redun- tide. At specific time intervals, reactions were subjected to addi-
dant and 93.7% complete (Table 1). Amplitudes were obtained from tional Bio-spin separations. Parallel experiments compared I-Ak
averaged intensities using TRUNCATE (CCP4, 1994). peptide binding utilizing I-Ak/CLIP molecules. 125I-radiolabeled
HEL(48±61) was used as the I-Ak reference peptide in competition
studies. To determine SDS-PAGE stability, I-A complexes con-Structure Determination and Refinement
taining 125I-labeled peptides were immunoprecipitated prior to elec-The structure of the I-Ag7/HEL complex was determined by molecular
trophoresis, with either 40 F anti-I-Ak or A42.7 anti-I-Ag7 monoclonalreplacement using AMoRe (CCP4, 1994). The top cross-rotation
antibodies and captured with protein A±Sepharose as described byfunction solutions for both molecules in the asymmetric unit were
Nelson et al. (1994). The resulting peptide complexes were run onobtained using the coordinates of I-Ak/HEL (PDB accession code
12% SDS-PAGE. Following drying, the gels were analyzed by phos-1IAK; Fremont et al., 1998). Translation functions were run in all
phorimaging (PhosphorImager 425E, Molecular Dynamics).possible P422 enantiomorphs, with the highest signal (correlation
coefficient 5 50%, R value 5 39% for all 8±4.0 AÊ data) unambigu-
T Cell Recognition of I-Ag7/Peptide Complexesously in space group P41212, consistent with the systematic ab-
We added 2.5 3 105 irradiated NOD APC and 1 3 104 T clonessences in the data. O (Jones et al., 1991) and CNS (Brunger et al.,
specific to I-Ag7/HEL(11±25) to wells in DMEM with 5% fetal calf1998) were used during multiple cycles of structure building and
serum. Cells were incubated with test peptides for 48±60 hr at 378Crefinement. Strict noncrystallographic symmetry (NCS) was initially
with 5% CO2, following which the reactions were pulsed with 1used in refinement and map calculations, with later rounds using
mCi of [3H]thymidine (Amersham) for 6 hr. Finally, the cells wereNCS restraint weights. The final stage of refinement had NCS re-
harvested onto paper filters with a 96-well Harvester (Skatron Instru-straints of 50 Kcal/mol AÊ 2, although earlier stages used up to 300
ments) and analyzed for radioactivity by scintillation beta counting.Kcal/mol AÊ 2. NCS restraints were used defining three equivalent
regions: the binding platform including the peptide, the a2 domain,
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